Psoriasis medications: The future

Abstract

AbstractIntroduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of keratinocytes and presenting as sharply demarcated, scaly, erythematous plaques and varying levels of systemic involvement.1‐3 The pathogenesis of the disease is multifactorial and includes immunologic, genetic, and environmental factors.3 Increased understanding of the involved immune‐mediated inflammatory pathways has led to the development of new targeted therapies.3 This review focuses on the safety and efficacy of novel topical, oral, and injectable therapeutic options for treatment of psoriasis.Objectives: The primary objective of this study is to present safety and efficacy data on current and upcoming topical, oral, and biologic therapies for the treatment of psoriasis.Methods: Review of randomized controlled trials on the efficacy and safety of current and upcoming topical, oral, and biologic therapies via an electronic literature search using PubMed, The Cochrane Library, ClinicalTrials.gov, and data presented at AAD VMX 2021.Results: A total of 15 oral, topical or biologic therapies were included and the latest clinical trial safety and efficacy data was presented for the following therapies: tapinarof, roflumilast, tofacitinib, deucravacitinib, baricitinib, abrocitinib, bimekizumab, sonelokimab, secukinumab, risankizumab, guselkumab, ustekinumab, ixekizumab, tildrakizumab, and brodalumab.Conclusion: There are many new and exciting topical, oral and biologic therapies for the treatment of psoriasis. With many novel biologics undergoing clinical trials, providers will have numerous options when deciding which therapy is best for each patient.